Randomized, Open-label, Parallel-group, Multi-centre Phase II Clinical Trial With Active Cellular Immunotherapy DCVAC/PCa in Patients With Localized Prostate Cancer After Primary Radical Prostatectomy
Phase of Trial: Phase II
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Stapuldencel-T (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors SOTIO
- 10 Jun 2017 Biomarkers information updated
- 23 May 2017 Status changed from active, no longer recruiting to completed.
- 30 Jun 2015 Planned End Date changed from 1 Mar 2017 to 1 Jun 2017 as per ClinicalTrials.gov record.